Analyst Research

Report Title Price
Provider: Reuters Investment Profile
$20.00
Provider: GlobalData
$125.00
Provider: Sadif Analytics Prime
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Guerbet SA's Lipiodol approved for reimbursement in Japan when used for Transcatheter Arterial Chemo-embolization


Wednesday, 27 Nov 2013 12:01pm EST 

Guerbet SA:Says its Guerbet Japan announced that the company's Lipiodol drug is approved for National Health Insurance reimbursement for Transcatheter Arterial Chemo-Embolization (TACE) for hepatocarcinoma cellular when used with Pfizer Japan Inc.'s Farmorubicin drug.Says this approval for insurance reimbursement follows Ministry of Health, Labor and Welfare (MHLW) approval of a new Lipiodol indication for adjustment of drugs and medical devices received by the company on Sep. 13, 2013. 

Company Quote

34.15
0.05 +0.15%
19 Dec 2014